Imperial College London has begun integrating C2N’s PrecivityAD2 blood test into primary care pathways for Alzheimer’s diagnosis, as part of the BEAD-PC study and the Davos Alzheimer’s Collaborative initiative.
A new study presented at ADLM 2026 shows a high-sensitivity biosensor can quantify the ESAT-6 protein in blood, distinguishing active tuberculosis from latent infection and other lung diseases.
The FDA has cleared Roche’s cobas BV/CV assay, a molecular test that detects bacterial vaginosis and Candida vaginitis from a single swab, enabling streamlined diagnosis on the cobas platform, according to Roche.
Researchers report that inherited CDK12 gene variants may increase risk for early, aggressive prostate cancer, suggesting inclusion of CDK12 in hereditary screening panels could improve risk identification in men.
New analysis suggests that higher-sensitivity testing could lower annual spending by more than $3 billion by reducing misdiagnosis.
Researchers identified coordinated lipid, metabolite, and protein signatures in symptomatic patients, supporting a multi-omic strategy for earlier ovarian cancer detection.
A new ultrasensitive blood test may detect Sjögren’s disease more than 10 years before symptoms appear by identifying chronically elevated interferon alpha levels in patient blood samples.
The assay measures lipoprotein(a) levels in molar units to improve cardiovascular risk assessment and standardization across laboratories.
ALZpath and Alamar Biosciences have expanded their partnership, granting Alamar commercial rights to use ALZpath’s pTau217 antibody in clinical blood tests for Alzheimer’s disease.
Researchers from Charité – Universitätsmedizin Berlin report that steatotic liver disease subtypes often shift over time, with 36% of MetALD patients reclassified within six months, suggesting a need for dynamic disease monitoring.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.